Adam Bonislawski

2 weeks ago | 360dx.com | Adam Bonislawski

NEW YORK – Major shareholders of high-sensitivity immunoassay outfit Quanterix reiterated their opposition to the company's plan to acquire Akoya Biosciences following the announcement of a $30 million securities purchase agreement between the two firms. Investment firm Kent Lake issued a statement on Monday opposing a securities purchase agreement that Quanterix entered into with Akoya Biosciences on April 2, under which Akoya may sell Quanterix up to $30 million in convertible notes.

3 weeks ago | 360dx.com | Adam Bonislawski

NEW YORK – With the US District Court for the Eastern District of Texas decision Monday vacating the US Food and Drug Administration's (FDA's) final rule on laboratory-developed tests (LDTs) a measure of clarity has been provided on the question of FDA's authority with regard to these tests — for decades a point of dispute between the agency and the clinical lab industry.

3 weeks ago | 360dx.com | Adam Bonislawski

NEW YORK – Cuts and freezes to federal funding for scientific research could lead to fewer academic spinouts and a reduced pipeline of investment opportunities in the life science tools space, said a number of industry investors and stakeholders.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – Public health and commercial laboratories are bringing molecular and serology testing online to help manage the ongoing measles outbreaks in Texas and New Mexico. While public health labs have sufficient capacity to handle the current case numbers, declining childhood vaccination rates could lead to larger outbreaks and increased demand for testing in coming years, suggested one clinical lab executive.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – While reporting an 11 percent jump year over year jump in its fourth quarter revenues, Quanterix on Monday also said cuts in academic research funding could weigh heavily on the firm’s revenues going forward. Quanterix reported Monday after the close of markets that for the three months ended Dec. 31, 2024, its fourth quarter revenues rose 11 percent to $35.2 million from $31.5 million in Q4 2023.